The rising global burden of obesity and type 2 diabetes mellitus (T2DM) increasingly manifesting as the comorbid condition ‘diabesity’ demands integrated therapeutic strategies that address their shared and complex pathophysiology. Conventional glucose-centric approaches to T2DM management often neglect the pivotal role of excess adiposity in disease progression. This review underscores the promise of mesoporous silica nanoparticles (MSNs) as next-generation nanocarriers for dual-action therapies, capable of co-delivering anti-obesity and antidiabetic agents. MSNs possess a highly tunable structure, including adjustable pore sizes, large surface areas, and modifiable surfaces, facilitating the efficient encapsulation and controlled release of multiple therapeutics. Their versatility allows for synergistic modulation of interconnected metabolic pathways implicated in obesity and T2DM. Functionalization with targeting ligands enables tissue-specific delivery particularly to adipose tissue and pancreatic β-cells while minimizing systemic exposure and off-target effects. Moreover, MSNs can be engineered for stimuli-responsive release, activated by metabolic cues such as hyperglycaemia or local acidosis, enabling temporally and spatially controlled drug administration. Preclinical evidence, encompassing In vitro assays and in vivo models, supports the therapeutic potential of MSNs in enhancing lipid metabolism and improving glycaemic control. For instance, delivery of microRNA-33 antagomirs via MSNs has been shown to reverse lipid dysregulation in murine models. Separately, MSN-based insulin carriers have demonstrated sustained glucose reduction and pancreatic tissue preservation. These findings highlight the potential of MSNs to revolutionise diabesity management by enhancing therapeutic efficacy, reducing dosing complexity, and improving patient compliance through multifaceted, targeted interventions.